This phase I trial is trying to determine the recommended dose of a new intravenous therapy (AMG 427) in patients with Acute Myeloid Leukaemia that has got worse or not responded to prior therapies.
This trial is treating patients with acute myeloid leukaemia.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1 First-In-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
This trial contains a dose-escalation and dose-expansion phase. AMG 427 will be administered intravenously at an escalating or maximum tolerated dose.
Recruiting Hospitals Read More
Not Recruiting Hospitals Read More